| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
The Week in Review provides an overview of the past week’s top health care content, including industry news and trends, Mayo Clinic and Mayo Clinic Laboratories news, and upcoming events.
Biden Administration Outlines Plan for Vaccinating Children Under 5
The White House released a fact sheet outlining the administration’s plans to get COVID-19 vaccines to children aged 6-months to 5-years-old, once the vaccine is fully approved for emergency use. Ten million vaccine doses are available for providers to preorder. Source: Axios
Moderna Says Updated Vaccine Works Better Against Omicron
Moderna released new data on its “bivalent” vaccine that targets both the original COVID-19 strains as well as the omicron variant. The company said the new vaccine led to an eight-fold increase in neutralizing antibodies. Source: The Hill
Monkeypox: CDC’s New Warning Level Explained
The CDC is now calling monkeypox a Level 2 concern, which indicates U.S. travelers should take precautions when traveling, such as wearing a mask. However, the risk to most Americans remains low. Source: The Hill
FDA Advisors Back Novavax COVID Shot
The Novavax shot is based on the traditional vaccine technology used to fight influenza and shingles, offering a distinctly different option to Americans who may be wary of the mRNA vaccines made by Pfizer and Moderna. Source: HealthDay
Disparities remain in opioid treatment access, Mayo Clinic study finds
A new study from Mayo Clinic finds ongoing gaps in access to prescriptions for a commonly used drug to treat opioid use disorder. The gap particularly affects older people, women and Black and Hispanic populations. Source: MPR News
Inclisiran effectively, safely lowers LDL in patients with prior cerebrovascular disease
“Patients with hyperlipidemia and established cerebrovascular disease are at an increased risk of future strokes or other cardiovascular events. In ischemic stroke survivors, treatment with statins and inhibitors of PCSK9 reduce recurrent cardiovascular events including stroke,” R. Scott Wright, MD, consultant in the divisions of structural heart disease and preventive cardiology and professor of medicine at Mayo Clinic, and colleagues wrote in a poster abstract. “With guidelines increasingly advocating lower LDL-C goals, add-on lipid-lowering therapies to statins may be required.” Source: Healio
